Impedimed Ltd (IPD) - Cash Flow Conversion Efficiency

Latest as of December 2025: -1.053x

Based on the latest financial reports, Impedimed Ltd (IPD) has a cash flow conversion efficiency ratio of -1.053x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-9.50 Million ≈ $-6.72 Million USD) by net assets (AU$9.02 Million ≈ $6.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Impedimed Ltd (IPD) defensive interval to measure how many days the company can operate on defensive assets alone.

Impedimed Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Impedimed Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Impedimed Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Impedimed Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Synex International Inc.
TO:SXI
0.061x
Federal International Holdings Bhd
KLSE:8605
-0.049x
LCC Infotech Limited
NSE:LCCINFOTEC
0.267x
Shanghai Broadband Technology Co Ltd
SHG:600608
0.540x
Zenta Group Company Limited
NASDAQ:ZTG
N/A
Axolot Solutions Holding AB
ST:AXOLOT
-0.008x
Green Earth Group N.V.
AS:HWK
0.038x
Dundas Minerals Ltd
AU:DUN
-0.089x

Annual Cash Flow Conversion Efficiency for Impedimed Ltd (2008–2025)

The table below shows the annual cash flow conversion efficiency of Impedimed Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Impedimed Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$20.50 Million
≈ $14.50 Million
AU$-14.64 Million
≈ $-10.36 Million
-0.715x -63.65%
2024-06-30 AU$40.74 Million
≈ $28.83 Million
AU$-17.79 Million
≈ $-12.59 Million
-0.437x -47.27%
2023-06-30 AU$60.88 Million
≈ $43.08 Million
AU$-18.05 Million
≈ $-12.77 Million
-0.296x +3.39%
2022-06-30 AU$51.04 Million
≈ $36.12 Million
AU$-15.66 Million
≈ $-11.08 Million
-0.307x +40.94%
2021-06-30 AU$25.51 Million
≈ $18.05 Million
AU$-13.26 Million
≈ $-9.38 Million
-0.520x +26.02%
2020-06-30 AU$27.36 Million
≈ $19.36 Million
AU$-19.22 Million
≈ $-13.60 Million
-0.702x +43.40%
2019-06-30 AU$15.79 Million
≈ $11.17 Million
AU$-19.59 Million
≈ $-13.86 Million
-1.241x -89.40%
2018-06-30 AU$35.80 Million
≈ $25.33 Million
AU$-23.46 Million
≈ $-16.60 Million
-0.655x -50.68%
2017-06-30 AU$58.80 Million
≈ $41.60 Million
AU$-25.57 Million
≈ $-18.09 Million
-0.435x -65.33%
2016-06-30 AU$85.25 Million
≈ $60.32 Million
AU$-22.42 Million
≈ $-15.86 Million
-0.263x +14.83%
2015-06-30 AU$34.84 Million
≈ $24.65 Million
AU$-10.76 Million
≈ $-7.61 Million
-0.309x +38.57%
2014-06-30 AU$13.53 Million
≈ $9.57 Million
AU$-6.80 Million
≈ $-4.81 Million
-0.503x +30.62%
2013-06-30 AU$10.59 Million
≈ $7.50 Million
AU$-7.67 Million
≈ $-5.43 Million
-0.724x -6.30%
2012-06-30 AU$17.31 Million
≈ $12.25 Million
AU$-11.80 Million
≈ $-8.35 Million
-0.682x -24.75%
2011-06-30 AU$20.68 Million
≈ $14.63 Million
AU$-11.30 Million
≈ $-7.99 Million
-0.546x -16.93%
2010-06-30 AU$22.23 Million
≈ $15.73 Million
AU$-10.39 Million
≈ $-7.35 Million
-0.467x +60.09%
2009-06-30 AU$10.07 Million
≈ $7.12 Million
AU$-11.79 Million
≈ $-8.34 Million
-1.171x -94.18%
2008-06-30 AU$12.30 Million
≈ $8.70 Million
AU$-7.42 Million
≈ $-5.25 Million
-0.603x --

About Impedimed Ltd

AU:IPD Australia Medical Devices
Market Cap
$8.66 Million
AU$12.23 Million AUD
Market Cap Rank
#27399 Global
#1372 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.06
All Time High
AU$1.68
About

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more